Vaccine (Adenoviral vector) · Immune activation, directed at HPV-16/18 E6 protein and HPV-16/18 E7 protein · developed by Precigen
PRGN-2009 is a gorilla-derived adenovirus vaccine expressing HPV-16 and HPV-18 E6 and E7 antigens, given subcutaneously. It is studied in combination with pembrolizumab in cervical cancer and other HPV-related malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06157151 | Phase 2 | Cervical Cancer | Recruiting | PGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cervical CancerHPV-Related CarcinomaHPV-Related MalignancyMetastatic Cervical CancerRecurrent Cervical Carcinoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the PGEN page.
See PGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PGEN catalysts and pipeline →